Read the September Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • FDA Approval for Darolutamide in Prostate Cancer
  • Elective Node Radiation Appears More Effective for Nodal Recurrence
  • DRE Is Still a Prognostic Tool
  • Validity of PROMIS Sexual Interest and Satisfaction Measures Post-RP
  • Toxicity of Prostate Only Versus Prostate & Pelvic Lymph Node IMRT
  • Doc Moyad’s No Bogus Science: “Boring B12 Testing & Vacuuming?!”
  • Obesity Tied to Worse Perioperative Outcomes of RP
  • Negative Predictive Value of Prostate Multi-Parametric MRI
  • Radiation Therapy May Have a Role in Oligometastatic Prostate Cancer
  • Men’s Testosterone Levels Determined by Where They Grow Up
  • Researchers Find Molecular Switch to Prolong Survival
  • Doctor Chodak’s Bottom Line

Posted in Uncategorized by with no comments yet.

Read the August 2019 Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Prostate Cancer Higher in 9/11 Responders – A Look at Why
  • ADT & Multiple Bone Properties
  • MRI Plus Systematic Sampling Ups First-Time Prostate Biopsy Hits
  • Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid & Initial ADT
  • Vitamin D Supplementation and Total Cancer Incidence and Mortality
  • Doc Moyad’s No Bogus Science: “PCa & Depression?!”
  • Socioenvironmental Adversity and Risk of PCa
  • Moderately Hypofractionated Proton Therapy for Localized PCa
  • ADT Use and Diagnosis of Dementia in Men with PCa
  • Body Fat Distribution Points to Prostate Cancer Aggressiveness
  • Doctor Chodak’s Bottom Line

Posted in Uncategorized by with no comments yet.

Read the July Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Misleading Advertising Claims by Proton Beam Therapy Centers
  • More is Not Better in Treatment of Metastatic CRPC
  • Apalutamide for Metastatic Castration-Sensitive Prostate Cancer
  • Time to BCR After RP and Efficacy of Salvage Radiotherapy
  • Evaluating the Safety of AS
  • Doc Moyad’s No Bogus Science: “Fruit Juice = Sugary Soda?!”
  • MRI-Targeted vs. Systematic Biopsy
  • Enzalutamide Joins Initial Treatment List for Metastatic PCa
  • Satisfaction with Care Among Men with Localized PCa
  • Doctor Chodak’s Bottom Line

Posted in Uncategorized by with no comments yet.

Read the June Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Packing a PUNCH in Prostate Cancer Chemo, ADT & Surgery
  • Gleason 8 PCa Diagnosed at Biopsy Frequently Downgraded
  • ‘Trexit’ – a Clean Break from Trans-Rectal Prostate Biopsies
  • Clinical Utility of CTC Androgen Splice Variant-7 Status
  • High-Fat, Diet-Induced Prostate Cancer Development
  • Doc Moyad’s No Bogus Science: “Breakfast is Not Important?!”
  • Clinical Validation of IsoPSA™
  • Prostate Cancer Metastases at Diagnosis on the Rise
  • Active Surveillance in Black Men with Low-Risk Prostate Cancer
  • Sipuleucel-T Could Be More Widely Used for Advanced Prostate Cancer
  • ‘Fake News’ in Urology
  • Doctor Chodak’s Bottom Line
  • New Entry in ‘Burgeoning Field’ of Prostate Cancer Therapy

Posted in Uncategorized by with no comments yet.

Read the May Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Chemo for Early-Stage PCa? RTOG 0521 Says Maybe
  • PET-Based Imaging Improves Metastases Detection in BCR
  • Long-Term ADT Underused for Prostate Cancer
  • Intervention Helps Prostate Cancer Patients with Choices
  • Doc Moyad’s No Bogus Science: “Take/Want Nothing!?”
  • Worry Postprostatectomy a Self-Fulfilling Prophecy
  • Carbon-Ion Radiotherapy for PCa & Risk of Second Cancers
  • Doctor Chodak’s Bottom Line
  • Validation of Androgen Receptor Splice Variant 7

Posted in Uncategorized by with no comments yet.

Read the April Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Active Surveillance for Prostate Cancer Triples in U.S.
  • Abiraterone & Mortality Risk from Cardiovascular Disease
  • Darolutamide Results Promising in Nonmetastatic PCa
  • Phase III Trial of PROSTVAC Stopped Early Due to Futility
  • Stereotactic Body Radiotherapy Shows Long-Term Safety in PCa
  • Doc Moyad’s No Bogus Science: “The Secret to Dog’s Long Life”
  • Radiological Agent Promising in Heavily-Treated mCRPC
  • Enzalutamide Plus ADT for Advanced Prostate Cancer
  • Minimal Benefit of Aspirin Post-Prostate Cancer Diagnosis
  • Doctor Chodak’s Bottom Line

Posted in Uncategorized by with no comments yet.

Read the March Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Does Castrate in Prostate Cancer Need Revision?
  • Adjuvant Docetaxel No Help in High-Risk Prostate Cancer
  • AS Safe for Prostate Cancer Patients Under 60 Years Old
  • Time Interval to Biochemical Failure – Surrogate End Point?
  • PCa Death Risk Linked to Post EBRT Time to PSA Nadir
  • Doc Moyad’s Column: “Follow Breast Cancer for Lifestyle?!”
  • Fusion Biopsies in AS Predict Prostate Cancer Progression
  • QoL But Sexual Dysfunction Common After Prostate Cancer
  • Low Carb Diet & Walking May Ease Adverse Effects of ADT
  • Doctor Chodak’s Bottom Line
  • Adding MRI Does Not Boost Prostate Cancer Upgrading

Posted in Uncategorized by with no comments yet.

Read the February Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • RP Beats Surveillance, or Does It?
  • Overactive Bladder Linked to ADT for Prostate Cancer
  • New, Quicker Test to Assess Risk of PCa Metastasis
  • Short- vs. Intermediate-Term AS with RT & Zoledronic Acid
  • Doc Moyad’s Column: “Restaurants = Weight Gain?!”
  • PCa Risk Higher in Men with Inflammatory Bowel Disease
  • Hypofractionated RT & Pca
  • Combination Strategy IDs Pca
  • Gleason 6 PCa More Lethal in Black Men
  • Gold Nanoparticles Could Destroy Prostate Cancer
  • Survival – Black vs. White Men Receiving Docetaxel
  • Surrogate Marker for ADT
  • Doctor Chodak’s Bottom Line

Posted in Uncategorized by with no comments yet.

Read the January Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Prostatectomy Beats Active Surveillance Long Term – or Does It?
  • Is No Surgery Feasible in Gleason 9 and 10 PCa?
  • Prostate Cancer Risk Lower in Long-Term Users of Lipid-Lowering Drugs
  • YouTube Videos Often Mislead on Prostate Cancer
  • Doc Moyad’s No Bogus Science: “Are Fish Oil Results a Little Fishy?!”
  • ADT May Be Less Beneficial for Gleason Score 9 to 10 Prostate Cancer
  • Doctor Chodak’s Bottom Line
  • Index of Articles Published in the 2018 Hot SHEET

Posted in Uncategorized by with no comments yet.

Read the December Us TOO Hotsheet

Click here to read these short Hotsheet articles:

  • Adding Radium-223 to Abiraterone No Help in Prostate Cancer
  • New Data on RT in Prostate Cancer Are “Practice Changing”
  • ADT plus Pelvic Node RT & Freedom from Prostate Cancer Progression
  • Better Outcomes with RT for Black Prostate Cancer Patients
  • Doc Moyad’s No Bogus Science: “VITAL = the End of the Vitamin D Debate? Nope!!”
  • CyberKnife® SBRT Results From 38 Institutions in More than 500 Men Followed Over Seven Years
  • Agent Orange Exposure Does Not Appear to Worsen Prostate Cancer Outcomes
  • Doctor Chodak’s Bottom Line

Posted in Uncategorized by with no comments yet.